ClinicalTrials.gg
CompletedNCT01613144EVOLVEUpdated Feb 25, 2022

OsseoScrew Versus Fenestrated Pedicle Screws Augmented With Polymethylmethacrylate

An observational study in Osteoporosis and Poor Bone Quality, sponsored by Alphatec Spine, Inc.. Completed at 10 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-02-25.

Sponsored by Alphatec Spine, Inc. · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
94
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Osteoporosis with a site in Belgium — 4 open to participants now, 5 under way, none of them phase 3. Osteoporosis · Belgium.

Started
2012
with 4 others
Observational
5 of 32
2 open now
Registered
19th of 32
by date
Lead sponsor
1 of 32
Alphatec Spine, Inc.

Among the 32 studies in Osteoporosis with a site in Belgium, this one is one of 5 that started in 2012, is one of 5 observational ones, and was the 19th registered.

Osteoporosis

1,602 studies on the registry are indexed under Osteoporosis; 209 are open to participants now.

Browse Osteoporosis studies →

Open to participants now

4 of the 32 studies in Osteoporosis with a site in Belgium are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Osteoporosis with a site in Belgium, or all of them as a file.
02

Study summary

The purpose of this clinical investigation was to collect clinical evidence of the safety and efficacy of the OsseoScrew System. The OsseoScrew System is intended to provide immobilization and stabilization of spinal segments in skeletally mature patients as an adjunct to fusion. The study was designed to compare the safety and efficacy of OsseoScrew compared to any other commercially available fenestrated pedicle screw system augmented with PMMA for posterior spinal fixation after surgical correction of spinal deformity or pathology.

Read the detailed description

This was a randomized, open-label, controlled, multi-center study in which patients were randomized in a 1:1 ratio to receive either the OsseoScrew or any commercially available fenestrated screw augmented with polymethylmethacrylate (PMMA) (Control group) for posterior spinal fixation after surgical correction of spinal deformity or pathology. The study was planned to include up to 150 skeletally mature patients with spinal instability and osteopenia at up to 10 sites. Patients were to return postoperatively at 6 weeks (± 2 weeks) and at 6, 12, and 24 months (± 2 months) for assessments.

03

Conditions studied

  • Osteoporosis
  • Poor Bone Quality

Keywords

  • Osteopenia
  • Stenosis
  • Instability
  • Tumor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

150 skeletally mature study subjects with spinal instability and osteopenia will be enrolled in the study. Subjects will be randomized 1:1 to the OsseoScrew or the control group.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. ≥ 18 years of age
  2. Spinal instability or deformity requiring fusion with instrumentation
  3. Osteopenia defined as (T-Score of less than -1.0)
  4. No response to nonoperative treatment modalities preceding enrollment.
  5. Subject is willing and able to provide and agrees to release medical information for purposes of this study and to return for scheduled follow-up evaluations

Exclusion criteria

Exclusion Criteria:

  1. Active systemic or local infection
  2. A less than the study duration
  3. disorders
  4. Currently an alcohol, solvent, or drug abuser
  5. Psychiatric or cognitive impairment that, in the opinion of the investigator, would interfere with the subject's ability to comply with the study requirements
  6. History of allergies to any of the device components including but not limited to commercially pure titanium, titanium alloy, polymethylmethacrylate or Zirconium Oxide (ZrO2)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
94 participants (actual)

Groups and cohorts

  • OsseoScrew

    Test Product: OsseoScrew Spinal Fixation System

    Device: OsseoScrew Spinal Fixation System

  • Fenestrated Screw

    Control Product: Any commercially available fenestrated screw system augmented with PMMA

Interventions

  • DeviceOsseoScrew Spinal Fixation System

    Surgical intervention

06

What researchers measure

Primary outcomes

  1. Safety Endpoint: Rate of device-related or PMMA-related complications

    The proportion of patients who were free from device-related or PMMA-related complications leading to revision, supplemental fixation, non-elective removal, or reoperation throughout the study. Complications included, but were not limited to device or PMMA fracture, device or PMMA-related loosening, device or PMMA-related device disassembly, device migration or PMMA extravasation.

    Time frame: 24 months

  2. Efficacy Endpoint: Successful radiographic fusion

    Presence of continuous bridging bone across the implant

    Time frame: 24 months

Secondary outcomes

  1. Oswestry Disability Index

    This is a measure of the patient's self reported permanent functional disability. Each section is scored on a 1-5 scale with 5 representing the greatest disability.

    Time frame: 24 months

  2. Visual Analogue Scale for back pain

    This is a measure of the characteristic or attitude that is believed to range across a continuum of values to measure pain intensity. The range of score is from 0 - 100. The patient marks on the line the point that they feel represents their perception of their current state. A higher score indicates greater pain intensity.

    Time frame: 24 months

  3. Adverse events

    Adverse event rates

    Time frame: 24 months

07

Study locations

10 sites
  • O.L. Vrouwziekenhuis
    Aalst, Belgium
  • CHIREC du Clinique
    Bruxelles, Belgium
  • ULB Hopital Erasme
    Bruxelles, Belgium
  • CHC St. Joseph
    Liege, Belgium
  • Katholisches Klinikum Koblenz - Montabaur/
    Koblenz, Germany
  • University Medical Center Mainz/
    Mainz, Germany
  • San Giovanni Addolorata Hospital
    Rome, Italy
  • Institut d'Assistència Sanitària
    Gerona, Spain
  • Hospital de Leon
    Leon, Spain
  • The Royal National Orthopaedic Hospital
    Stanmore, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2012, a primary completion of Feb 2017 and a completion of Nov 2017. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2012
First posted
Jun 7, 2012
Start
May 2012
Primary completionActual
Feb 12, 2017
CompletionActual
Nov 8, 2017
Last update
Feb 25, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01613144
Lead sponsor
Alphatec Spine, Inc.
Responsible party
Sponsor
First posted
Jun 7, 2012
Start date
May 2012
Primary completion
Feb 12, 2017
Completion
Nov 8, 2017
Last update
Feb 25, 2022

Study contacts

Bita Ghadimi
study director · Alphatec Spine, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion